%0 Journal Article %1 Wynendaele.1999 %A Wynendaele, W. %A Derua, R. %A Hoylaerts, M. F. %A Pawinski, A. %A Waelkens, E. %A Bruijn, E. A. %A Paridaens, R. %A Merlevede, W. %A van Oosterom, A. T. %D 1999 %J Ann.Oncol. %K A Adult Aged Assay Biological Endothelial Enzyme-Linked Factor Factors Female Growth Humans Immunosorbent Lymphokines Male Markers Middle Neoplasms Neovascularization Nonparametric Pathologic RANGE Reference Research Sensitivity Specificity Statistics Tumor Values Vascular analysis and blood diagnosis methods %N 8 %P 965-971 %T Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo? %U PM:10509160 %V 10 %X BACKGROUND: Serum VEGF levels are elevated in cancer patients and are used as a tumor marker in different malignancies. We have measured VEGF levels in different blood compartments in cancer patients and healthy volunteers in order to assess the most suitable way of processing blood for measuring VEGF as a marker of tumor-angiogenesis. PATIENTS AND METHODS: VEGF concentrations were analyzed by an enzyme-linked immunosorbent assay in serum (VEGFS), EDTA plasma (VEGFEDTA), citrated plasma (VEGFC), CTAD-plasma (VEGFCTAD), platelet poor plasma (VEGFPPP), platelet rich plasma after induction of platelet activation (VEGFPRP). Platelet activation was assessed by measuring PF4 concentrations in different plasma samples. RESULTS: We observed higher VEGFS (P = 0.0027), VEGFEDTA (P = 0.003) and VEGFPPP (P = 0.0007) levels in cancer patients than in volunteers; VEGFPRP concentrations showed no significant difference (P = 0.208). Analysis of the correlation between VEGFplt and VEGFS in cancer patie

@article{Wynendaele.1999, abstract = {BACKGROUND: Serum VEGF levels are elevated in cancer patients and are used as a tumor marker in different malignancies. We have measured VEGF levels in different blood compartments in cancer patients and healthy volunteers in order to assess the most suitable way of processing blood for measuring VEGF as a marker of tumor-angiogenesis. PATIENTS AND METHODS: VEGF concentrations were analyzed by an enzyme-linked immunosorbent assay in serum (VEGFS), EDTA plasma (VEGFEDTA), citrated plasma (VEGFC), CTAD-plasma (VEGFCTAD), platelet poor plasma (VEGFPPP), platelet rich plasma after induction of platelet activation (VEGFPRP). Platelet activation was assessed by measuring PF4 concentrations in different plasma samples. RESULTS: We observed higher VEGFS (P = 0.0027), VEGFEDTA (P = 0.003) and VEGFPPP (P = 0.0007) levels in cancer patients than in volunteers; VEGFPRP concentrations showed no significant difference (P = 0.208). Analysis of the correlation between VEGFplt and VEGFS in cancer patie}, added-at = {2010-02-05T11:28:39.000+0100}, author = {Wynendaele, W. and Derua, R. and Hoylaerts, M. F. and Pawinski, A. and Waelkens, E. and Bruijn, E. A. and Paridaens, R. and Merlevede, W. and van Oosterom, A. T.}, biburl = {https://www.bibsonomy.org/bibtex/2c1500038f6cd1aaf008de83c84186463/kanefendt}, interhash = {6b4d1f6f91238fe72489c67ba262f497}, intrahash = {c1500038f6cd1aaf008de83c84186463}, journal = {Ann.Oncol.}, keywords = {A Adult Aged Assay Biological Endothelial Enzyme-Linked Factor Factors Female Growth Humans Immunosorbent Lymphokines Male Markers Middle Neoplasms Neovascularization Nonparametric Pathologic RANGE Reference Research Sensitivity Specificity Statistics Tumor Values Vascular analysis and blood diagnosis methods}, number = 8, pages = {965-971}, timestamp = {2010-02-05T11:28:48.000+0100}, title = {Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo?}, url = {PM:10509160}, volume = 10, year = 1999 }